CAR-based cell therapies for systemic lupus erythematosus
Abstract. The remarkable efficacy of chimeric antigen receptor (CAR) T cell therapy in hematological malignancies has provided a solid basis for the therapeutic concept, wherein specific pathogenic cell populations can be eradicated by means of targeted recognition. During the past few years, CAR-ba...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer
2025-03-01
|
| Series: | Chinese Medical Journal |
| Online Access: | http://journals.lww.com/10.1097/CM9.0000000000003406 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850235165465378816 |
|---|---|
| author | Yiyang Wang Liangjing Lu Shuang Ye Qiong Fu Xiangxiang Pan |
| author_facet | Yiyang Wang Liangjing Lu Shuang Ye Qiong Fu Xiangxiang Pan |
| author_sort | Yiyang Wang |
| collection | DOAJ |
| description | Abstract. The remarkable efficacy of chimeric antigen receptor (CAR) T cell therapy in hematological malignancies has provided a solid basis for the therapeutic concept, wherein specific pathogenic cell populations can be eradicated by means of targeted recognition. During the past few years, CAR-based cell therapies have been extensively investigated in preclinical and clinical research across various non-tumor diseases, with particular emphasis in the treatment of autoimmune diseases (ADs), yielding significant advancements. The recent deployment of CD19-directed CAR T cells has induced long-lasting, drug-free remission in patients with systemic lupus erythematosus (SLE) and other systemic ADs, alongside a more profound immune reconstruction of B cell repertoire compared with conventional immunosuppressive agents and B cell-targeting biologics. Despite the initial success achieved by CAR T cell therapy, it is critical to acknowledge the divergences in its application between cancer and ADs. Through examining recent clinical studies and ongoing research, we highlight the transformative potential of this therapeutic approach in the treatment of SLE, while also addressing the challenges and future directions necessary to enhance the long-term efficacy and safety of CAR-based cell therapies in clinical practice. |
| format | Article |
| id | doaj-art-eb32d6f31fd14e16b6e351a2ce90d3d9 |
| institution | OA Journals |
| issn | 0366-6999 2542-5641 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Wolters Kluwer |
| record_format | Article |
| series | Chinese Medical Journal |
| spelling | doaj-art-eb32d6f31fd14e16b6e351a2ce90d3d92025-08-20T02:02:24ZengWolters KluwerChinese Medical Journal0366-69992542-56412025-03-01138552353010.1097/CM9.0000000000003406202503050-00003CAR-based cell therapies for systemic lupus erythematosusYiyang Wang0Liangjing Lu1Shuang Ye2Qiong Fu3Xiangxiang Pan1 Department of Rheumatology, Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Shanghai 200127, China1 Department of Rheumatology, Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Shanghai 200127, China1 Department of Rheumatology, Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Shanghai 200127, China1 Department of Rheumatology, Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Shanghai 200127, ChinaAbstract. The remarkable efficacy of chimeric antigen receptor (CAR) T cell therapy in hematological malignancies has provided a solid basis for the therapeutic concept, wherein specific pathogenic cell populations can be eradicated by means of targeted recognition. During the past few years, CAR-based cell therapies have been extensively investigated in preclinical and clinical research across various non-tumor diseases, with particular emphasis in the treatment of autoimmune diseases (ADs), yielding significant advancements. The recent deployment of CD19-directed CAR T cells has induced long-lasting, drug-free remission in patients with systemic lupus erythematosus (SLE) and other systemic ADs, alongside a more profound immune reconstruction of B cell repertoire compared with conventional immunosuppressive agents and B cell-targeting biologics. Despite the initial success achieved by CAR T cell therapy, it is critical to acknowledge the divergences in its application between cancer and ADs. Through examining recent clinical studies and ongoing research, we highlight the transformative potential of this therapeutic approach in the treatment of SLE, while also addressing the challenges and future directions necessary to enhance the long-term efficacy and safety of CAR-based cell therapies in clinical practice.http://journals.lww.com/10.1097/CM9.0000000000003406 |
| spellingShingle | Yiyang Wang Liangjing Lu Shuang Ye Qiong Fu Xiangxiang Pan CAR-based cell therapies for systemic lupus erythematosus Chinese Medical Journal |
| title | CAR-based cell therapies for systemic lupus erythematosus |
| title_full | CAR-based cell therapies for systemic lupus erythematosus |
| title_fullStr | CAR-based cell therapies for systemic lupus erythematosus |
| title_full_unstemmed | CAR-based cell therapies for systemic lupus erythematosus |
| title_short | CAR-based cell therapies for systemic lupus erythematosus |
| title_sort | car based cell therapies for systemic lupus erythematosus |
| url | http://journals.lww.com/10.1097/CM9.0000000000003406 |
| work_keys_str_mv | AT yiyangwang carbasedcelltherapiesforsystemiclupuserythematosus AT liangjinglu carbasedcelltherapiesforsystemiclupuserythematosus AT shuangye carbasedcelltherapiesforsystemiclupuserythematosus AT qiongfu carbasedcelltherapiesforsystemiclupuserythematosus AT xiangxiangpan carbasedcelltherapiesforsystemiclupuserythematosus |